Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Conditions
- ASCVD
- Atherosclerotic Cardiovascular Disease
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Cancer
Interventions
- DRUG: Evolocumab
- DRUG: Statin
Sponsor
Xiang Xie
Collaborators